The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.
about
The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004Anti-endotoxin vaccines: back to the futurePrior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumoniaVaccines for preventing pneumococcal infection in adultsInjectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary diseaseVaccines for preventing pneumococcal infection in adultsInjectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary diseaseModulation of the lung inflammatory response to serotype 8 pneumococcal infection by a human immunoglobulin m monoclonal antibody to serotype 8 capsular polysaccharide.Use of licensed vaccines for active immunization of the immunocompromised hostWhat happened to the streptococci: overview of taxonomic and nomenclature changesGuidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleenPneumococcal and influenza vaccination: current situation and future prospectsPolicymaking based on CERs: changes in costs are not the same as changes in benefits.Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trialsSerotype-specific mortality from invasive Streptococcus pneumoniae disease revisitedA Review of Pneumococcal Vaccines: Current Polysaccharide Vaccine Recommendations and Future Protein AntigensMethodological criticisms in the evaluation of Pneumococcal Conjugate Vaccine effectivenessCase-Control Studies to Assess the Effectiveness of VaccinesBacterial Infections Following Splenectomy for Malignant and Nonmalignant Hematologic DiseasesA systems biology approach to the effect of aging, immunosenescence and vaccine responsePneumococcal Vaccination in High-Risk Individuals: Are We Doing It Right?A molecular mucosal adjuvant to enhance immunity against pneumococcal infection in the elderlyGuidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and preventionThe Streptococcus pneumoniae capsule is required for full virulence in pneumococcal endophthalmitisStreptococcus pneumoniae Cell-Wall-Localized Phosphoenolpyruvate Protein Phosphotransferase Can Function as an Adhesin: Identification of Its Host Target Molecules and Evaluation of Its Potential as a VaccinePandemic influenza and healthcare demand in the Netherlands: scenario analysisPneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease.Pneumococcal vaccine in the elderly: a useful but forgotten vaccine.Cost-effectiveness of pneumococcal polysaccharide vaccine among healthcare workers during an influenza pandemic.Dynamic modeling for pandemic influenza.Where the data are deficient: a field evaluation of the effectiveness of pneumococcal vaccination in remote Australia.Somatic hypermutation and diverse immunoglobulin gene usage in the human antibody response to the capsular polysaccharide of Streptococcus pneumoniae Type 6B.Factors influencing early and late mortality in adults with invasive pneumococcal disease in Calgary, Canada: a prospective surveillance studyInvasive pneumococcal infections among persons with and without underlying medical conditions: implications for prevention strategies.Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumoniaCandidate vaccine sequences to represent intra- and inter-clade HIV-1 variation.The effect of age on the response to the pneumococcal polysaccharide vaccine.Use of HL-60 cell line to measure opsonic capacity of pneumococcal antibodiesThe putative proteinase maturation protein A of Streptococcus pneumoniae is a conserved surface protein with potential to elicit protective immune responsesEvaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines
P2860
Q21261529-7B0A0645-CE47-45E5-B78B-A7D889618DAFQ22305428-5CDD1914-7791-46B1-85DF-D93092FD23B0Q23911823-78748B8A-F484-49C7-99B6-3F9E281C401DQ24201474-3557F3C3-120E-4C04-BFE8-C78FEC97D12FQ24236699-3CBEC7EE-BE21-4482-B8ED-9B027BD987B4Q24242290-ABB29D9B-A8BB-4B84-B843-EEBBE00EFA94Q24243866-38CA3E6D-A9B6-4232-B640-0D1ACBA2B0B2Q24532019-437E8271-1326-445A-9BB1-4211A82D1174Q24533456-C73A6883-4644-4E81-9EAF-9D5008191BF6Q24535684-5BBA25A2-B136-453E-8827-95F0264FC106Q24655614-C138F595-C65D-434E-AA4F-2CC48AD6F634Q24675532-BC1B611E-4B5B-48EE-838C-C92E1499135FQ24795396-69620347-D7A8-4DBB-8E97-571427D26AF5Q24795536-C87069A0-DC4D-4182-AAC6-990791C760B0Q24803495-D3BBB6BD-0EB0-441F-B68D-07B8D04780AFQ26753152-BB570058-81BB-462E-9560-18527C37A276Q26770693-6594FCD0-22A3-418F-A681-36B075857BA9Q26775607-DAB8F8BD-05CE-48C3-824A-8BCD53A0694EQ26778773-F1FE8B19-87A6-43C4-B36F-84AD4D2A4ECEQ26994749-7D136EF6-C02A-4F1F-8635-489BFB0F05FDQ28070059-73898C4E-C6C6-4012-A3BA-8393585F2123Q28084760-84BA30E4-4580-4371-B2DD-84A21336D30AQ28201389-DD3BF361-E7AB-444E-8837-AD1E46BB9520Q28386753-4B8C7DCF-FA6F-4E9C-B1EA-8DD3B22C097BQ28550871-A1277929-E2EA-44C3-9159-0249E2C45AB1Q30233416-3A9442F5-AEAB-4609-9CDA-19502B7656E9Q30238816-95652F35-7096-4194-84B5-68FF2440E177Q30378584-4646E4DE-24AD-4F49-9B47-61EBA09747D6Q30386616-2C27724F-549F-4697-BF89-A5F7E8CE5CAAQ30419587-7A1977F0-DF83-4A26-A2D1-7463B5183471Q30665414-0CCA3D9B-DA43-42DA-A57C-9EF83A10742EQ31064166-20915E0C-0452-4140-A448-6D096B385343Q31141633-739C5A93-F897-4AA1-B0F6-318A2F50D50AQ33353828-0B9466D3-E94B-4773-8192-37FD9E958D87Q33360868-311C047C-2E00-4BC2-B51D-6F10AF2B9FE2Q33509288-DBFCA0FE-3A41-4FA2-8C2E-9CBB484BAFB8Q33539419-0B243050-1B5E-4AA2-B5AA-65C6007E71B6Q33593722-4ABC22CD-8F45-4E91-81EC-6621C04D3990Q33598106-74526E76-09D0-48D5-98FB-8BF736E4C8E4Q33613509-8303E377-62C3-40AA-B6AF-F143D260ECE7
P2860
The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
1991年學術文章
@zh
1991年學術文章
@zh-hant
name
The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.
@en
The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.
@nl
type
label
The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.
@en
The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.
@nl
prefLabel
The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.
@en
The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.
@nl
P2093
P1476
The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.
@en
P2093
Austrian R
Clemens JD
Margolis A
Parcells V
Schroeder D
Shapiro ED
P304
P356
10.1056/NEJM199111213252101
P407
P577
1991-11-01T00:00:00Z